Methods of detecting tumor cells

Sample evaluation. Not a TreMonti report. Not legal advice. Generated 2026-08-28 for UT Arlington US10570461B2.

Screen (Tyler process)

• PI: Samir M. Iqbal, PhD (Purdue 2007). Now Associate Dean for Research and Industry Partnerships at Grand Valley State University; previously Professor and Chair at UT Rio Grande Valley and an NSF TIP Program Director. Leads the Nano-Bio Lab. h-index 29, roughly 3,248 citations. No startup linked to this patent. (Iqbal CV, Nano-Bio Lab, GVSU announcement)
• Technology / TRL: Label-free tumor-cell detection with anti-EGFR aptamer-coated substrates and morphology metrics (Hausdorff distance, pseudopod count). Estimated TRL 3-4: demonstrated on cultured mouse tumor cells and human glioblastoma cell lines, no clinical specimens. (Google Patents)
• Market: Circulating tumor cell (CTC) and liquid biopsy. The global CTC market is estimated at $14.0B in 2025, forecast to reach $39.0B by 2033 at a 13.9% CAGR. (Grand View Research)
• Time-to-market / capital: 5-10 years and significant capital for clinical validation, prototype integration, and FDA clearance.
• Funding: An NSF CAREER award (2009) funded the underlying work; an NSF confirmatory license was recorded in 2025. No private or venture funding found.
• Customers: Hospitals, oncology clinics, reference laboratories, academic research labs, and pharmaceutical companion-diagnostic developers.

Ratings

• Commercialization Potential: Medium
• Technology Readiness: Medium
• Protectable / Enforceable IP: Medium
• Market Opportunity: High
• Product Benefit: Medium

Ready-for-market narrative: Not ready for clinical use yet. The method needs validation on patient specimens and a defined regulatory pathway before any commercial use outside research.

Commercial application

Clinicians need non-invasive ways to find and monitor tumor cells. Tissue biopsy is invasive, costly, and hard to repeat. This method captures circulating tumor cells from a biological sample on an aptamer-coated surface and classifies them by shape, which could support early detection, treatment selection, and recurrence monitoring. Label-free operation should also mean less sample prep and lower reagent cost than fluorescent antibody workflows.

Technical description

A flat substrate (glass, silicon, or polymer) is coated with anti-EGFR DNA aptamers. Tumor cells that overexpress EGFR stick to the surface; most normal cells do not. Time-lapse microscopy captures images at roughly 4 frames per minute, and software computes the Hausdorff distance between successive cell outlines, counts pseudopods, and measures boundary non-uniformity. Tumor cells show larger shape changes and more pseudopods than non-tumor cells.

Demonstrated results:

• Mouse tumor cells: ~392 cells/mm² captured on anti-EGFR substrates versus ~7 cells/mm² on mutant controls (n=12 per group, P<0.01).
• Human glioblastoma cells: ~117 cells/mm² on anti-EGFR versus ~4 cells/mm² on mutant controls (n=12, P<0.01).
• Selectivity: hGBM cells captured from a mixed population with fibroblasts.
• Nano-textured PDMS substrates improved capture to ~150 cells/mm² versus ~26 on mutant controls.
• Tumor cells on anti-EGFR surfaces changed shape within 30 minutes; cells on mutant surfaces did not.

Every demonstration used cultured cell lines. No patient blood, tissue, or clinical specimens were tested.

Competitive advantage

Key benefits

• Label-free detection: no fluorescent labels, no target modification, minimal sample preparation.
• Marker-agnostic morphology readout: classifies captured cells by shape instead of a single surface marker such as EpCAM.
• Intact cells for downstream analysis: captured cells remain usable for single-cell genomics, culture, or drug-sensitivity testing.
• Synthetic aptamers: consistent lot to lot and potentially cheaper than antibody reagents.
• Compatible with nano-textured surfaces and electrical sensing: the broader patent family includes nanogap electrode variants; this patent covers the morphology method only.

Competing companies

Market and trends

The global circulating tumor cell market is estimated at $14.0B in 2025 and forecast to reach $39.0B by 2033 at a 13.9% CAGR.[^1] The U.S. CTC market is forecast to reach $10.16B by 2030 at a 12.77% CAGR.[^2] The broader liquid-biopsy market (CTCs, ctDNA, and extracellular vesicles) was estimated at $4.03B in 2025 and is forecast to reach $7.05B by 2030 at an 11.8% CAGR.[^3] Market Research Future gives an independent CTC estimate of $6.2B in 2025 rising to $19.46B by 2035 at a 12.12% CAGR.[^4]

Sub-segments and drivers:

• CTC detection and enrichment methods hold the largest technology share (50.7% of revenue).[^5]
• Clinical applications lead research (68.4% of revenue).[^5]
• Kits and reagents are the largest product segment.[^5]
• Blood is the largest specimen type.[^5]
• North America holds the largest regional share (41.4%).[^5]
• Hospitals and clinics are the largest end-use segment (37.8%).[^5]
• Key drivers: rising cancer prevalence, demand for non-invasive diagnosis, advances in CTC isolation, early-detection demand, and precision-oncology adoption.[^5]

[^1]: Grand View Research, "Circulating Tumor Cells Market Size & Share Report, 2025-2033," https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market
[^2]: Grand View Research, "U.S. Circulating Tumor Cells Market Report," https://www.grandviewresearch.com/industry-analysis/us-circulating-tumor-cells-market-report
[^3]: MarketsandMarkets, "Liquid Biopsy Market by Application, Region - Global Forecast to 2030," https://www.marketsandmarkets.com/Market-Reports/liquid-biopsy-market-13966350.html
[^4]: Market Research Future, "Circulating Tumor Cell Market Research Report," https://www.marketresearchfuture.com/reports/circulating-tumor-cell-market-1362
[^5]: Grand View Research, "Circulating Tumor Cells Market Size & Share Report, 2025-2033," https://www.grandviewresearch.com/industry-analysis/circulating-tumor-cells-market

Development directions

• Validate on clinical specimens: whole blood and patient-derived circulating tumor cells.
• Address aptamer stability in serum and nonspecific binding with chemical modifications or better buffers.
• Integrate the substrate, imaging, and classifier into one prototype cartridge or instrument.
• Run head-to-head studies against FDA-cleared platforms (CellSearch, Parsortix).
• Build a quality-management system and pick a regulatory pathway (510(k), De Novo, or PMA) based on intended use.
• License or co-develop with an IVD or liquid-biopsy company for capital, distribution, and clinical expertise.

Regulatory issues

This method has no FDA clearance. A clinical diagnostic would need premarket review and clinical studies; the exact pathway (510(k), De Novo, or PMA) depends on intended use, predicate devices, and risk classification. Laboratory-developed-test use may be possible under current CMS/FDA oversight but is not a commercial path. Verify current requirements with FDA and a regulatory consultant before committing to a development plan.

Potential partners